Literature DB >> 12530043

Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer.

Christos Tsigris1, Anastasios J Karayiannakis, Konstantinos N Syrigos, Andrew Zbar, Theodoros Diamantis, Nikolaos Kalahanis, Dimitrios Alexiou.   

Abstract

BACKGROUND: Both tissue c-erbB-2 expression and serum levels the shed protein have been shown to correlate with tumour stage in a range of adenocarcinomas. This study measured serum and urinary c-erbB-2 levels in patients with gastric cancer, assessing their role in cancer-specific survival and the effects of resectional surgery. PATIENTS AND METHODS: Serum and urinary c-erbB-2 concentrations were measured with commercial enzyme-linked immunosorbent assay in 41 healthy controls and in 54 gastric cancer patients. Serum and urinary c-erbB-2 levels in cancer patients were determined before and 7 days following tumour surgery.
RESULTS: Preoperative serum and urinary c-erbB-2 levels in gastric cancer patients were significantly higher than those in controls although there were no significant associations between these levels and tumour pathology. Serum c-erbB-2 levels decreased significantly after radical resection of the primary tumour and were an independent prognostic factor for survival, whereas there were no changes in urinary c-erbB-2 levels after surgery or an association with patient survival.
CONCLUSION: Gastric cancer patients show higher serum and urinary c-erbB-2 levels compared to healthy controls. Preoperative serum c-erbB-2 concentration decreases significantly after radical resection of the primary tumour and is an independent prognostic factor for patient survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530043

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.

Authors:  Eleftherios Vairaktaris; Lambros Goutzanis; Stavros Vassiliou; Sofia Spyridonidou; Emeka Nkenke; Georgios Papageorgiou; Pashalis Strantzias; Andreas Lazaris; Christos Yapijakis; Efstratios Patsouris
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-18       Impact factor: 4.553

2.  Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients.

Authors:  Taek Sang Kim; Hyun Yul Rhew; Hyun Yong Hwang
Journal:  Korean J Urol       Date:  2011-12-20

Review 3.  Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Kecheng Zhang; Jianxin Cui; Hongqing Xi; Shibo Bian; Liangang Ma; Weisong Shen; Jiyang Li; Ning Wang; Bo Wei; Lin Chen
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

4.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

5.  The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer.

Authors:  Xueyan Dong; Guoqing Wang; Guoqing Zhang; Zhaohui Ni; Jian Suo; Juan Cui; Ai Cui; Qing Yang; Ying Xu; Fan Li
Journal:  Diagn Pathol       Date:  2013-03-19       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.